Abstract
Rapid decontamination of the skin is the single most important action to prevent dermal absorption of chemical contaminants in persons exposed to chemical warfare agents (CWA) and toxic industrial chemicals (TICs) as a result of accidental or intentional release. Chemicals on the skin may be removed by mechanical means through the use of dry sorbents or water. Recent interest in decontamination systems which both partition contaminants away from the skin and actively neutralize the chemical has led to the development of several reactive decontamination solutions. This article will review the recently FDA-approved Reactive Skin Decontamination Lotion (RSDL) and will summarize the toxicity and efficacy studies conducted to date. Evidence of RSDL’s superior performance against vesicant and organophosphorus chemical warfare agents compared to water, bleach, and dry sorbents, suggests that RSDL may have a role in mass human exposure chemical decontamination in both the military and civilian arenas.
Keywords: VX, soman, vesicants, sulfur mustard, dermal, decontamination, reactive skin decontamination lotion, chemical warfare, Rapid decontamination, chemical warfare agents (CWA), toxic industrial chemicals (TICs), decontamination systems, several reactive decontamination solutions, Reactive Skin Decontamination Lotion (RSDL), Evidence of RSDL’s.
Current Pharmaceutical Biotechnology
Title:Reactive Skin Decontamination Lotion (RSDL) for the Decontamination of Chemical Warfare Agent (CWA) Dermal Exposure
Volume: 13 Issue: 10
Author(s): M. D. Schwartz, C. G. Hurst, M. A. Kirk, S. J.D. Reedy and E. H. Braue
Affiliation:
Keywords: VX, soman, vesicants, sulfur mustard, dermal, decontamination, reactive skin decontamination lotion, chemical warfare, Rapid decontamination, chemical warfare agents (CWA), toxic industrial chemicals (TICs), decontamination systems, several reactive decontamination solutions, Reactive Skin Decontamination Lotion (RSDL), Evidence of RSDL’s.
Abstract: Rapid decontamination of the skin is the single most important action to prevent dermal absorption of chemical contaminants in persons exposed to chemical warfare agents (CWA) and toxic industrial chemicals (TICs) as a result of accidental or intentional release. Chemicals on the skin may be removed by mechanical means through the use of dry sorbents or water. Recent interest in decontamination systems which both partition contaminants away from the skin and actively neutralize the chemical has led to the development of several reactive decontamination solutions. This article will review the recently FDA-approved Reactive Skin Decontamination Lotion (RSDL) and will summarize the toxicity and efficacy studies conducted to date. Evidence of RSDL’s superior performance against vesicant and organophosphorus chemical warfare agents compared to water, bleach, and dry sorbents, suggests that RSDL may have a role in mass human exposure chemical decontamination in both the military and civilian arenas.
Export Options
About this article
Cite this article as:
D. Schwartz M., G. Hurst C., A. Kirk M., J.D. Reedy S. and H. Braue E., Reactive Skin Decontamination Lotion (RSDL) for the Decontamination of Chemical Warfare Agent (CWA) Dermal Exposure, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273191
DOI https://dx.doi.org/10.2174/138920112802273191 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiobesity Therapy: Emerging Drugs and Targets
Current Medicinal Chemistry Design and Study of Piracetam-like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs
Current Pharmaceutical Design Role of Reactive Oxygen Species in Tumor Necrosis Factor-alpha Induced Endothelial Dysfunction
Current Hypertension Reviews “Branched Tail” Oxyquinoline Inhibitors of HIF Prolyl Hydroxylase: Early Evaluation of Toxicity and Metabolism Using Liver-on-a-chip
Drug Metabolism Letters Optimal Sedation for the Ventilation of Critically Ill Patients
Current Respiratory Medicine Reviews Future of Cardiac Pacemaker – an Update of Biological Pacemaker Patents
Recent Patents on Biomedical Engineering (Discontinued) Interaction between Thienopyridines and Proton Pump Inhibitors
Cardiovascular & Hematological Disorders-Drug Targets Insulin Therapy, Insulin Resistance and Vascular Dysfunction
Current Vascular Pharmacology The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets
Current Pharmaceutical Design New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Angiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology
Current Medicinal Chemistry Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Directions in Antipsychotic Target Identification using Gene Arrays
Current Drug Targets - CNS & Neurological Disorders New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets A Review on the Prevalence of Depression in Malaysia
Current Psychiatry Reviews Pathophysiology of Coronary Collaterals
Current Cardiology Reviews The Pharmacological Effects of Novokinin; a Designed Peptide Agonist of the Angiotensin AT<sab>2</sab> Receptor
Current Pharmaceutical Design Therapeutic Monitoring of Plasma Digoxin for COVID-19 Patients Using a Simple UPLC-MS/MS Method
Current Pharmaceutical Analysis